Main content

    Renal and Urinary Tract Cancer Clinical Trials

    CPMC Cancer ServicesOpens new window

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
    Description: The purpose of this study is to determine the efficacy and safety of nivolumab versus placebo in participants who have undergone radical surgery for invasive urothelial cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older with invasive urothelial cancer at high risk of recurrence originating in the bladder, ureter, or renal pelvis; must have had radical surgical resection (e.g. radical cystectomy), performed within the last 90 days; must have disease free status as determined by imaging within 4 weeks of dosing
    Status: Coming soon
    Contact: Madeline Decker, 415-600-3613, Email: GasperP@cpmcri.org about Study BMS CA209-274

    Title: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
    Description: Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects 18 y/o and older with confirmed renal cell carcinoma
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperP@cpmcri.org about Study SWOG S0931 (Everest)

    Title: A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma
    Description: This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study EA8141

    • updated April 2016

    Back to top